Apex Biotechnology Corp (1733) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Apex Biotechnology Corp stock TWD 26.06, price TWD 28.75, that is 9.4% below the price, quality 70 out of 100. Rating: overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 20.38 TWD – 42.65 TWD · fair‑value band 19.91 TWD – 33.49 TWD · the 28.75 TWD price screens above the 26.06 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Apex Biotechnology in your weekly email
Every Wednesday you see whether Apex Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide.
Show moreShow less
It offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing systems. The company also provides pesticide residue check systems; and care management and tele-health services.
The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.
Stock analysis
Apex Biotechnology Corp (1733) currently trades at 28.75 TWD, while our model-based Fair Value estimate is 26.06 TWD, 9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 30.28 TWD per share, and 6 of the 25 models we run sit above the 28.75 TWD price.
Bear case: the Asset-Based group reads lowest at 11.28 TWD, and 19 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: 19.91 TWD (bear) to 33.49 TWD (bull), the price of 28.75 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Apex Biotechnology Corp reported revenue of 1.9B TWD in FY2025 versus 2.1B TWD in FY2021, a compound −2.3%/yr. Reported net income was 163M TWD in FY2025, compounding −5.2%/yr from FY2021.
Key figures
Market cap 2.9B TWD (≈ $88.0M) Micro · P/E ratio 15.2 · P/S ratio 1.55 · EPS (TTM) 1.89 TWD · Dividend yield 4.5% · Net margin 10.2% · Return on equity 10.4% · Return on assets (EBIT) 6.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −9%, 1733 screens cheaper than that median.
Fair Value models
Bear19.91 TWDFair Value 26.06 TWDBull33.49 TWD
Price 28.75 TWD · Downside -9.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5059 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Start year 2020 (pandemic). Over 10 years: +0.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.1%
Dividend (yield on the price)4.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.1% vs −4.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +7.7% a year for the price.
Compare Apex Biotechnology Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−9.7% · Above median
Profitability
Return on equity (12 months)10.4% · Above median
Return on assets6.8% · Above median
Net margin (12 months)10.2% · Above median
Operating margin (12 months)9.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−7.7% · Bottom 25%
Dividend yield (12 months)4.5% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)15.2× · Cheapest 25%
P/B1.55× · Cheaper than median
P/S (12 months)1.55× · Cheaper than median
Price / free cash flow (fiscal year)19.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Apex Biotechnology Corp (1733) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 26.06 TWD versus a price of 28.75 TWD, about 9% lower (overvalued).
What is the fair value of 1733?
Our model-based fair value for Apex Biotechnology Corp is 26.06 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 28.75 TWD.
What is the quality score of 1733?
Apex Biotechnology Corp has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Apex Biotechnology Corp (1733)?
Our model-based price target is the fair value of 26.06 TWD (as of Nov 9, 2026) from 25 valuation models. Cautious scenario 19.91 TWD, optimistic scenario 33.49 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Apex Biotechnology Corp stock forecast for 2026?
Our models put fair value at 26.06 TWD, about 9% lower versus a price of 28.75 TWD (overvalued). Cautious scenario 19.91 TWD, optimistic scenario 33.49 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Apex Biotechnology Corp (1733)?
Apex Biotechnology Corp reported trailing-twelve-month revenue of about 1.9B TWD (latest available figure, as of Nov 9, 2026).
Does Apex Biotechnology Corp pay a dividend?
Apex Biotechnology Corp currently shows a dividend yield of 4.52% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Apex Biotechnology Corp (1733) and when is the ex-dividend date?
Apex Biotechnology Corp pays a dividend of 1.30 TWD per share a year, a dividend yield of 4.5%. The last ex-dividend date was Jun 9, 2026. The payout ratio is 68.8% of earnings. Free cash flow covers the dividend 1.15 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Apex Biotechnology Corp (1733)?
For today's price to be fair in a discounted-cash-flow model, Apex Biotechnology Corp would have to grow free cash flow by +9.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.6 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 1733 use?
Our models discount Apex Biotechnology Corp at 11.8 %: a base by market capitalisation (micro), damped by beta 0.27, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Apex Biotechnology Corp that is +9.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Apex Biotechnology Corp (1733) delivered so far?
Over the past 5 years revenue at Apex Biotechnology Corp grew -0.6 % a year. The price currently implies free-cash-flow growth of +9.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Apex Biotechnology Corp (1733) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Apex Biotechnology Corp (+9.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Apex Biotechnology Corp (1733)?
The free-cash-flow yield on the price is 5.15 %: that much free cash flow Apex Biotechnology Corp produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Apex Biotechnology Corp (1733)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Apex Biotechnology Corp it is 26.06 TWD per share (as of Nov 9, 2026), against a price of 28.75 TWD. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Apex Biotechnology Corp stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 1733 trades above its calculated fair value: price 28.75 TWD, fair value 26.06 TWD, a gap of about −9% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1733?
No. The price is what the market pays today (28.75 TWD); the fair value is what the company's own numbers justify (26.06 TWD). For Apex Biotechnology Corp the two are 2.69 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Apex Biotechnology Corp worth?
The market values Apex Biotechnology Corp at about 2.9B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 28.75 TWD; our models calculate a fair value of 26.06 TWD per share.
What do the bullish and bearish scenarios say about 1733?
Our models span a range for Apex Biotechnology Corp: cautious scenario 19.91 TWD, base 26.06 TWD, optimistic 33.49 TWD per share (as of Nov 9, 2026, price 28.75 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1733?
Apex Biotechnology Corp trades at a price-to-earnings ratio of 15.2 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26.06 TWD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 28.2. Other multiples: P/B 1.6, P/S 1.6, EV/EBITDA 10.5.
How solid is the balance sheet of Apex Biotechnology Corp (1733)?
Balance-sheet figures for Apex Biotechnology Corp (as of Nov 9, 2026): return on equity 10.4%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 1733 from its 52-week high?
Apex Biotechnology Corp trades at 28.75 TWD, about 12% below its 52-week high of 32.80 TWD and 2% above the low of 28.20 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 26.06 TWD is for.
Which stocks are comparable to Apex Biotechnology Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Apex Biotechnology Corp stock attractive at the current price?
The data as of Nov 9, 2026: price 28.75 TWD, calculated fair value 26.06 TWD (−9%), Quality Score 70/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1733 calculated?
We run Apex Biotechnology Corp through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 26.06 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Apex Biotechnology Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Apex Biotechnology Corp (1733)?
The closing price on Nov 9, 2026 was 28.75 TWD. Our model-based fair value is 26.06 TWD, about 9% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Apex Biotechnology Corp right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Apex Biotechnology Corp (1733) come from?
Earnings per share at Apex Biotechnology Corp grew −2.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +0.5 %, EBIT margin −7.7 %, tax rate +0.8 %, residual (interest, one-offs) +4.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Apex Biotechnology Corp
How large is the market capitalisation of Apex Biotechnology Corp (1733)?
The market capitalisation of Apex Biotechnology Corp is 2.9B TWD (≈ $88.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Apex Biotechnology Corp (1733)?
The price-to-sales ratio of Apex Biotechnology Corp is 1.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Apex Biotechnology Corp (1733)?
Earnings per share at Apex Biotechnology Corp are 1.89 TWD (price ÷ EPS = P/E 15.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Apex Biotechnology Corp (1733)?
The dividend yield of Apex Biotechnology Corp is 4.5% (payout 68.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Apex Biotechnology Corp (1733)?
The net margin of Apex Biotechnology Corp is 10.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Apex Biotechnology Corp (1733)?
The return on equity (ROE) of Apex Biotechnology Corp is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Apex Biotechnology Corp (1733)?
On an EBIT basis the return on assets of Apex Biotechnology Corp is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Apex Biotechnology Corp (1733)?
The operating margin of Apex Biotechnology Corp is 9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Apex Biotechnology Corp (1733)?
Revenue at Apex Biotechnology Corp is growing −7.7% versus a year earlier (3y avg −4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Apex Biotechnology Corp (1733)?
Earnings per share at Apex Biotechnology Corp are growing +28.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Apex Biotechnology Corp (1733) hold?
Apex Biotechnology Corp holds more cash than debt, 418M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Apex Biotechnology Corp in the live analysis
One click puts Apex Biotechnology Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026